The Modulatory Effect of Adipose-Derived Stem Cells on Endometrial Polyp Fibroblasts.
Reema FadoulTharwat Haj KhalilIdan RedenskiDaniel OrenAsaf ZigronAvishalom SharonAmiel A DrorMizied FalahSamer SroujiPublished in: Stem cells and development (2022)
Endometrial polyps (EPs) are benign overgrowths of the endometrium, with the potential to cause severe complications, ranging from discomfort to inflammation and infertility. Dysfunction of endometrial fibroblasts may be a critical component leading to the development of polyps. Although surgical intervention is the common remedy for severe cases, it comes with drawbacks, including infection, bleeding, and risk of damage to the cervix and adjacent tissues. Adipose-derived mesenchymal stromal cells (ASCs) are at the focus of modern medicine, as key modulators of tissue homeostasis, inflammation, and tissue repair, rendering them prime candidate agents for tissue regeneration and cell-based therapies. In this study, EPs were isolated from patients admitted to the OB/GYN department at the Galilee Medical Center and extracted fibroblasts (endometrial polyp fibroblasts, EPFs) were isolated and characterized. ASCs were isolated from healthy patients. The effect of EPF- and ASC-conditioned media (CM) on polyp-derived fibroblasts was evaluated, in both 2D and 3D assays, as well as on the expression of matrix-related gene expression. Herein, EPFs exposed to ASC-CM exhibited reduced migration, invasion, contraction of hydrogels, and extracellular matrix deposition, compared with those exposed to EPF-CM. Altogether, this study suggests that ASCs may have a modulating effect on fibroblasts involved in forming EPs and may serve as the basis for conservative treatment strategies aimed at treating severe cases of EPs.
Keyphrases
- extracellular matrix
- gene expression
- oxidative stress
- endometrial cancer
- randomized controlled trial
- stem cells
- early onset
- ejection fraction
- newly diagnosed
- poor prognosis
- end stage renal disease
- signaling pathway
- type diabetes
- metabolic syndrome
- risk factors
- cell therapy
- risk assessment
- skeletal muscle
- nlrp inflammasome
- preterm birth
- drug induced
- polycystic ovary syndrome
- smooth muscle
- hyaluronic acid